Rafael Holdings, Inc. splits its revenue into 6 lines in its filings. The largest line in fiscal 2026, which ended Jul 31, 2026 was Product Revenue at $519,000, 59% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jul 31, 2026
|
FY 2025
Jul 31, 2025
|
FY 2024
Jul 31, 2024
|
FY 2023
Jul 31, 2023
|
FY 2022
Jul 31, 2022
|
FY 2021
Jul 31, 2021
|
FY 2020
Jul 31, 2020
|
FY 2019
Jul 31, 2019
|
FY 2018
Jul 31, 2018
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1
|
0
|
1
|
0
|
0
|
1
|
5
|
5
|
4
|
| Product Revenue |
1
+0.8%
share 59.4%
|
1
share 1716.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Real Estate |
—
|
—
|
—
|
—
|
0
-48.9%
share 100.0%
|
1
share 100.0%
|
—
|
—
|
—
|
| Rental Third Party |
0
+19.8%
share 27.0%
|
0
share 656.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Rental Related Party |
0
+6.2%
share 13.6%
|
0
share 373.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Infusion Technology |
—
|
0
share 310.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Infusions Technology Revenue |
—
|
0
share 310.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RFL (NYSE)
- Fiscal year ends
- July 31
- Incorporated in
- DE
- Headquarters
- Newark, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1713863
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.